HSV1 viremia with fulminant hepatitis as opportunistic sequela in severe COVID-19
2021; Springer Science+Business Media; Volume: 101; Issue: 1 Linguagem: Inglês
10.1007/s00277-021-04417-y
ISSN1432-0584
AutoresLuca Roncati, Antonio Manenti, Luca Fabbiani, Claudia Malagoli, Vincenzo Nasillo, Beatrice Lusenti, Massimo Lupi, Giuliana Zanelli, Tiziana Salviato, Matteo Costantini, Tommaso Trenti, Antonino Maiorana,
Tópico(s)Viral gastroenteritis research and epidemiology
ResumoDear Editor,Coronavirus disease 2019 (COVID-19) is a global public health emergency and new knowledge about it and its etiological agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is deemed necessary in order to reduce the death burden around the world [1].In this regard, a 67-yearold Italian male patient, dyslipidemic, hypertensive, active smoker, and a 49-year-old Italian male patient, affected by hypertrophic cardiomyopathy, were admitted to the intensive care unit (ICU) in feverish state (> 38.1 °C) for SARS-CoV-2 pneumonia complicated with acute respiratory distress syndrome, characterized by diffuse alveolar damage (DAD) and diffuse alveolar hemorrhage (DAH) (Fig. 1a).Upon ICU admission, IgG and IgM serum immunoassay against herpes simplex virus 1 (HSV1) turned out negative (IgG: 3 U/mL and 1 U/mL; IgM: 5 U/mL and 2 U/mL; negativity ranges: IgG < 7.5 U/mL and IgM < 16 U/mL).During the hospitalization period, both the patients received ab initio oxygen and antipyretic and steroid therapy (methylprednisolone: 80 mg/ day for 1 day; then 40 mg/day for 3 days; and, at last, 20 mg/
Referência(s)